Elena López-Miranda

High Frequency of ERBB2 Activating Mutations in Invasive Lobular Breast Carcinoma with Pleomorphic Features

Juan Manuel Rosa-Rosa, Tamara Caniego-Casas, Susanna Leskelä et al. · Cancers · 2019 · 47 citations · Full text

Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial

José Manuel Pérez-García, Antonio Llombart‐Cussac, María Gión et al. · European Journal of Cancer · 2021 · 38 citations

Metastatic Breast Cancer, Oncology, Breast Oncology +10

A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

Glenn J. Hanna, Anastasios Stathis, Elena López-Miranda et al. · Cancer Research Communications · 2023 · 36 citations · Full text

Use of Bevacizumab as a First-Line Treatment for Metastatic Breast Cancer

Luís Manso, Fernando Moreno, Rosario Mayorga Márquez et al. · Current Oncology · 2015 · 18 citations · Full text

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Komal Jhaveri, Meritxell Bellet, Nicholas C. Turner et al. · Clinical Cancer Research · 2023 · 18 citations · Full text